Evidence map›Paper›PMID 31379816›Full record

ArticleFrontiers in immunology2019

Influences of Vitamin A on Vaccine Immunogenicity and Efficacy.

Rhiannon R Penkert, Hannah M Rowe, Sherri L Surman, Robert E Sealy, Jason Rosch, Julia L Hurwitz

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Retinoid metabolism: new insights.Journal of molecular endocrinology · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rhiannon R PenkertDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States.
Hannah M RoweDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States.
Sherri L SurmanDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States.
Robert E SealyDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States.
Jason RoschDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States.
Julia L HurwitzDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States.
St. Jude Children's Research Hospital · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
NCI NIH HHS P30 CA021765
6 · The paper itself

Abstract

Vitamin A deficiencies and insufficiencies are widespread in developing countries, and may be gaining prevalence in industrialized nations. To combat vitamin A deficiency (VAD), the World Health Organization (WHO) recommends high-dose vitamin A supplementation (VAS) in children 6-59 months of age in locations where VAD is endemic. This practice has significantly reduced all-cause death and diarrhea-related mortalities in children, and may have in some cases improved immune responses toward pediatric vaccines. However, VAS studies have yielded conflicting results, perhaps due to influences of baseline vitamin A levels on VAS efficacy, and due to cross-regulation between vitamin A and related nuclear hormones. Here we provide a brief review of previous pre-clinical and clinical data, showing how VAD and VAS affect immune responses, vaccines, and infectious diseases. We additionally present new results from a VAD mouse model. We found that when VAS was administered to VAD mice at the time of vaccination with a pneumococcal vaccine (Prevnar-13), pneumococcus (T4)-specific antibodies were significantly improved. Preliminary data further showed that after challenge with

Indexed as

AnimalsDietary SupplementsFemaleImmunogenicity, VaccineMaleMiceMice, Inbred C57BLPneumococcal VaccinesPregnancyVaccinationVitamin AVitamin A Deficiency13-valent pneumococcal vaccinePneumococcal VaccinesVitamin Aimmune responsepneumococcussupplementationvaccinesvitamin A

Identifiers

PMID31379816
PMCPMC6651517
OpenAlexW2961184424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.